226 million R&D costs have been lost, Biotech terminates an ADC project under development

After accumulative investment of 226 million yuan, Biotech finally announced the termination of the ADC project BAT8001 (recombinant humanized anti-HER2 monoclonal antibody-maytansine conjugate for injection) clinical trials on HER2-positive breast cancer .

It is understood that BAT8001 is an antibody conjugate drug independently developed by Biotech.

As for the reason for the termination of the project, Biotech issued an announcement to clarify that the phase III clinical study of BAT8001 for HER2-positive breast cancer is a domestic multi-center, randomized, open, positive control, and superiority phase III clinical study.

At the same time, Biotech stated that according to the Frost & Sullivan report, the total market size of anti-HER2 ADC drugs for HER2-positive breast cancer in China is expected to be approximately 17 million yuan in 2020, and is expected to grow at a compound annual growth rate of 207.

It is understood that Biotech is the first pharmaceutical company on the Sci-tech Innovation Board to publicly disclose the termination of clinical trials.

The ADC drug that Biotech has terminated the research is a hot topic in antibody drug research and development at home and abroad in recent years.

Forecasts from PR Newswire show that the ADC drug market will reach 9.

Among them, Roche’s Kadcyla (enmetrastuzumab) and Takeda/Seattle Genetics’ Adcetris (vebutuximab for injection) have been launched in China.

In preparations for ADC R&D, domestic companies, in addition to Rongchang Biotech, also have more than 10 local pharmaceutical companies, including Hengrui Pharmaceuticals, Kelun Pharmaceuticals, Zhejiang Pharmaceuticals, Shanghai Pharmaceuticals, and Fudan Zhangjiang.